Food Deserts Sample Clauses

Food Deserts. The 2008 Farm Bill prompted the USDA to study geographical access to food throughout the United States (United States Department of Agriculture, 2009). The Farm Bill defined a new term, “food deserts,” to mean that there is “limited access to affordable and nutritious food, particularly such an area composed of predominantly lower income neighborhoods and communities.” Food deserts were originally defined as “living far from a supermarket, where 1 mile was used in urban areas and 10 miles were used in rural areas” ("Definitions,"). Low-income census tracts and access to vehicles are sometimes included in food desert analysis. Increased access to supermarkets, rather than convenience stores, usually results in healthier diets (Xxxxxx, Story, & Xxxxxx, 2009). In urban areas, neighborhood disparities can manifest themselves in the form of negative health outcomes. Food Insecurity and Diabetes Type two diabetes can make management of food insecurity much more difficult. Food insecure individuals have poorer self-reported diabetes self-efficacy (Xxxxxxxx et al., 2016). There is little research done on the prevalence of food insecurity within a population of type two diabetic patients. In 2014, 1/3 food insecure households had a person in the household with diabetes ("Feeding America's Response to Diabetes and Food Insecurity," 2015). Households that are food secure spend a median of $45/person on food each week. In comparison, food insecure households spend $35/person (Xxxxxxxx & Xxxxxxxxxxx, 2010). This expenditure deficit makes it difficult to prioritize “diabetic friendly” foods such as vegetables, fruits, and protein, and much easier to spend it on inexpensive and easily accessible foods, which are usually highly processed and carbohydrate-rich. Research has only just begun to incorporate food insecurity variables into datasets. One study of food insecurity found a national prevalence of 42.7% (n=16,651) (Kushel, Xxxxx, Xxx, & Xxxx, 2006). This is much higher than the national prevalence of food insecurity because this population (n=16,651) was only low-income adults. Using data from the National Health and Nutrition Examination Survey (NHANES), Kushel et. al found that 6% of adults with diabetes self-reported as food insufficient, which translates to represent over 568,600 Americans (95% CI, 369,400- 768,800) (Xxxxxx, Xxxxxxxxxx, Xxxxxxxx, Xxxxxxxx, & Xxxxxxx, 2001). Another NHANES study found that among subjects who had a self-reported diagnosis of diabet...
Sample 1
AutoNDA by SimpleDocs
Food Deserts. Distressed geographic areas where either a substantial number or percentage of residents has low access to a supermarket or large grocery store. For the purpose of satisfying the requirements of Goal 3, Measure 1, a Food Desert must either: (1) be a census tract determined to be a Food Desert by the U.S. Department of Agriculture (USDA), in its USDA Food Access Research Atlas; (2) be a census tract adjacent to a census tract determined to be a Food Desert by the USDA, in its USDA Food Access Research Atlas; which has a median family income less than or equal to 120 percent of the applicable Area Median Family Income; or (3) be a Geographic Unit as defined in 12 CFR 1805.201(b)(3)(ii)(B), which a. individually meets at least one of the criteria in 12 CFR 1805.201(b)(3)(ii)(D), and b. has been identified as having low access to a supermarket or grocery store through a methodology that has been adopted for use by another governmental or philanthropic healthy food initiative. The Recipient may use the 2015 and 2010 food desert data layers currently displayed in the Food Atlas to identify a USDA defined food desert (see: xxxx://xxx.xxx.xxxx.xxx/data-products/food-access-research-atlas.aspx ).
Sample 1
Food Deserts. The Parties will ensure that Black communities have access to affordable and nutritious food.
Sample 1
Food Deserts. Distressed geographic areas where either a substantial number or percentage of residents has low access to a supermarket or large grocery store. For the purpose of satisfying the requirements of Goal 3, Measure 1, a Food Desert must either:
Sample 1

Related to Food Deserts

  • Electrical Service Electrical service for new construction or a renovated existing building shall be 480/277-volt, 3-phase, 4-wire or approved equal. Service shall be sized for HVAC and other mechanical system(s) loads, lighting, general building services, and dedicated computer based office equipment loads. 5 xxxxx per square foot shall be provided for lighting and general service receptacles. Size of neutral conductor of 3- phase circuits shall be twice that of phase conductor to accommodate potential harmonic currents associated with computer system electronic power supplies and fluorescent lighting fixtures electronic ballasts. An adequately sized 3 phase “wye” wound step down transformer shall be provided to supply 208/120-volt, 3 phase power, for lighting, general service receptacles and dedicated computer based office equipment. Dedicated, isolated ground circuits shall be supplied from separate isolated ground power distribution panel(s). Lighting circuits shall be supplied from separate lighting panel(s). Panels shall have 20% spare capacity and be complete with 10% spare breakers of each size, but no less than 1 spare. No more than 4 duplex receptacles shall be connected to any single 20-amp dedicated isolated ground circuit or general service circuit.

  • ELECTRICAL SERVICES A. Landlord shall provide electric power for a combined load of 3.0 xxxxx per square foot of useable area for lighting and for office machines through standard receptacles for the typical office space.

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, Registration Statement, the Pricing Disclosure Package or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with applicable laws, rules, regulations and policies of the Food and Drug Administration of the U.S. Department of Health and Human Services (the “FDA”) or any committee thereof or of any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are materially inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Pricing Disclosure Package or the Prospectus; for such studies that have been or are being conducted, the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by foreign government or drug or medical device regulatory agencies, or foreign health care facility Institutional Review Boards; and no investigational new drug application filed by or on behalf of the Company or any of its subsidiaries with the FDA has been terminated or suspended by the FDA, and neither the FDA nor any applicable foreign regulatory agency has commenced, or, to the knowledge of the Company, threatened to initiate, any action to place a clinical hold order on, or otherwise terminate, delay or suspend, any proposed or ongoing studies conducted or proposed to be conducted by or on behalf of the Company or any of its subsidiaries.

  • Service Area (a) SORACOM shall provide the SORACOM Air Global Service within the area designated on the web site of SORACOM (the “Service Area”), provided, that, the Service Area may be different if stated otherwise as specified by SORACOM separately. However, within the Service Area, you may not use the SORACOM Air Global Service in places where transmissions are difficult to send or receive.

  • FDA As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a “Pharmaceutical Product”), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.

  • Quality Control A. Controlled Affiliate agrees to use the Licensed Marks and Name only in connection with the licensed services and further agrees to be bound by the conditions regarding quality control shown in attached Exhibit A as they may be amended by BCBSA from time-to-time.

  • Cost of Metering The Issuer shall not be obligated to pay any costs associated with the routine metering duties set forth in this Section 2, including the costs of installing, replacing and maintaining meters, nor shall the Issuer be entitled to any credit against the Servicing Fee for any cost savings realized by the Servicer as a result of new metering and/or billing technologies.

  • Regulatory Compliance a. Monitor compliance with the 1940 Act requirements, including:

  • Government Approval, Regulation, etc No authorization or approval or other action by, and no notice to or filing with, any governmental authority or regulatory body or other Person is required for the due execution, delivery or performance by the Borrower of this Amendment.

Time is Money Join Law Insider Premium to draft better contracts faster.